Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,345 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,345 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total transaction of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80.

Hims & Hers Health Trading Down 5.4 %

Shares of Hims & Hers Health stock opened at $13.65 on Friday. The business has a 50-day moving average price of $18.36 and a two-hundred day moving average price of $16.81. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74. The company has a market cap of $2.93 billion, a P/E ratio of -1,365.00 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The firm’s revenue was up 51.8% on a year-over-year basis. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HIMS shares. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America boosted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and raised their price objective for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.29.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after acquiring an additional 136,907 shares in the last quarter. Forerunner Ventures Management LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth about $86,836,000. Renaissance Technologies LLC grew its stake in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the period. Dimensional Fund Advisors LP increased its position in Hims & Hers Health by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after buying an additional 193,507 shares in the last quarter. Finally, Farallon Capital Management LLC raised its stake in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.